Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...3536373839404142434445...170171»
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Clinical, Review, Journal:  Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. (Pubmed Central) -  Aug 24, 2022   
    The studies provided very low-certainty evidence that LMWH may reduce the risk of asymptomatic DVT compared to no prophylaxis, but it is uncertain how this directly relates to incidence of DVT or PE in healthy people undergoing KA. There is probably little or no difference in adverse effects (including major and minor bleeding), but data relating to these outcomes were limited by low numbers of events in the studies reporting these outcomes.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Preclinical, Journal:  CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. (Pubmed Central) -  Aug 24, 2022   
    These PD observations suggest that modulating thrombin generation-by means of factor Xa inhibition-in adjunct to antiplatelet therapy provides effective antithrombotic effects, supporting the efficacy and safety findings of a DPI strategy observed in clinical trials.  CM-352 treatment, by diminishing MMPs and rivaroxaban-associated fibrinolytic effects, might be a novel antihemorrhagic strategy for rivaroxaban-associated ICH.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Retrospective data, Journal:  Anticoagulation for atrial fibrillation in people with serious mental illness in the general hospital setting. (Pubmed Central) -  Aug 24, 2022   
    Over recent years, DOAC prescription rates have increased among AF patients with SMI in acute hospitals. More research is needed to confirm whether the introduction of DOACs has reduced OAC treatment gaps in people with serious mental illness and to assess whether the use of DOACs has improved health outcomes in this population.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg., colchicine / Generic mfg.
    Trial primary completion date:  ACT COVID19: Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (clinicaltrials.gov) -  Aug 23, 2022   
    P3,  N=6667, Active, not recruiting, 
    More research is needed to confirm whether the introduction of DOACs has reduced OAC treatment gaps in people with serious mental illness and to assess whether the use of DOACs has improved health outcomes in this population. Trial primary completion date: May 2022 --> Feb 2022
  • ||||||||||  warfarin / Generic mfg.
    Observational data, Retrospective data, Journal:  Bleeding events in the emergency department with warfarin versus novel oral anticoagulants: A five-year analysis. (Pubmed Central) -  Aug 22, 2022   
    Our findings indicate that rates of major and minor bleeding complications in patients taking NOACs are similar to those in patients taking warfarin. While warfarin was associated with fewer complications than NOACs in terms of gastrointestinal bleeding, the risk of intracranial bleeding, was similar between the groups.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above. (Pubmed Central) -  Aug 22, 2022   
    Under the assumption that hepatic function is not impaired in post-Fontan patients, PBPK and popPK simulations indicated that half of the rivaroxaban doses for the same body weight given to pediatric patients treated for acute VTE would yield in pediatric post-Fontan patients exposures similar to the exposure observed in adult patients receiving 10 mg rivaroxaban once-daily for thromboprophylaxis. Simulation-derived doses (7.5 mg rivaroxaban once-daily for body weights 30 to <50 kg and 10 mg once-daily for body weights ≥50 kg) were therefore included in the recent US label of rivaroxaban for thromboprophylaxis in children aged ≥2 years congenital heart disease who have undergone the Fontan procedure.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial completion date, Trial primary completion date, Surgery:  DOAC/VKA: DOAC Versus VKA After Cardiac Surgery (clinicaltrials.gov) -  Aug 22, 2022   
    P2,  N=206, Not yet recruiting, 
    Simulation-derived doses (7.5 mg rivaroxaban once-daily for body weights 30 to <50 kg and 10 mg once-daily for body weights ≥50 kg) were therefore included in the recent US label of rivaroxaban for thromboprophylaxis in children aged ≥2 years congenital heart disease who have undergone the Fontan procedure. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Nonspecific Tools Performed Better in Discriminating Major Bleeding From Direct Oral Anticoagulants Than Specific Tools in a Real-World Population With Atrial Fibrillation (Zone 4, Science and Technology Hall, Level 3; Poster Board no. 4083) -  Aug 20, 2022 - Abstract #AHA2022AHA_6483;    
    DOACs are increasingly being prescribed in the US compared to warfarin because of lower bleeding risk overall, but the proportion of Emergency Department visits involving DOACs-related bleeding increased from 2.3% in 2011 to 37.9% in 2017...A retrospective cohort study was carried out with 2,364 Caucasians diagnosed with non-valvular AF and treated with rivaroxaban or apixaban at the University of Michigan Health System...Conclusion. ATRIA, HEMORR2HAGES, and ORBIT were the tools that performed better in discriminating major bleeding in AF patients if compared to HAS-BLED and ABS.
  • ||||||||||  HF.APS.P49. #Hashtag-Check Out the Clinical Cases in Heart Failure (Zone 2, Science and Technology Hall, Level 200) -  Aug 20, 2022 - Abstract #AHA2022AHA_6044;    
    This study determined the distribution of AXA, PT, and APTT in patients administered apixaban, edoxaban, and rivaroxaban. DESCRIPTION This poster session will feature exciting clinical cases in heart failure.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Rivaroxaban in the treatment of TEK-related venous malformation. (Pubmed Central) -  Aug 18, 2022   
    Slow flow through the blood vessels can lead to localized intralesional thromboses, which can cause debilitating pain and impair quality of life. We present a case of venous malformation due to a variant in the TEK gene in a 38-year-old woman in whom treatment with low dose rivaroxaban was successful in controlling symptoms of chronic localized intravascular coagulation.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report. (Pubmed Central) -  Aug 17, 2022   
    The DVT disappeared after systematic heparin treatment and oral rivaroxaban for 2 months. DVT occurred in a kidney transplant recipient with COVID-19 who was not bedridden and might manifest when the clinical status was exacerbated during hospitalization.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation. (Pubmed Central) -  Aug 17, 2022   
    Under rivaroxaban treatment, a total of seven metabolites changed, the lipid and glycosylphosphatidylinositol biosynthesis pathways were altered and the panel consisting of avocadene, prenyl glucoside and phosphatidylethanolamine showed predictive ability with an AUC of 0.86 for the discovery dataset and 0.82 for the validation. The study showed that plasma metabolomic analyses hold the potential to differentiate nonvalvular atrial fibrillation and can help to monitor the effect of rivaroxaban anticoagulation.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  INTERMITTENT: Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients (clinicaltrials.gov) -  Aug 16, 2022   
    P=N/A,  N=100, Recruiting, 
    The study showed that plasma metabolomic analyses hold the potential to differentiate nonvalvular atrial fibrillation and can help to monitor the effect of rivaroxaban anticoagulation. Unknown status --> Recruiting | Phase classification: P4 --> PN/A | Trial completion date: Nov 2021 --> Nov 2023 | Trial primary completion date: Nov 2020 --> Nov 2022
  • ||||||||||  ivermectin oral / Generic mfg.
    LUNG CAVITY: A RARE FINDING IN COVID-19 (Convention Center Exhibit Hall: Poster Area) -  Aug 16, 2022 - Abstract #CHEST2022CHEST_1860;    
    The lung cavity in a COVID patient is an under-recognized entity. This case report highlights the need for further studies to determine the cause of cavitation, which could be related to COVID infection or its treatment.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Andexanet Alfa Induced Heparin Resistance Further Complicated By A Protamine Anaphylactoid Reaction (Hall C) -  Aug 15, 2022 - Abstract #ASA2022ASA_4258;    
    During the case, baseline ACT was 115 and required 354 U/kg of heparin to achieve a satisfactory ACT of 219. Upon surgical completion protamine was given for heparin reversal leading to hypoxia, elevated peak airway pressure, hypotension from profound vasoplegia as evident on TEE, and a serum tryptase was normal.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg., ropivacaine / Generic mfg.
    Combined Femoral And Fascia Iliaca Nerve Block In A Critically Ill Patient (Hall C) -  Aug 15, 2022 - Abstract #ASA2022ASA_4077;    
    Pain relief was achieved and mental status improved. We wish to provide a case of using regional anesthesia for pain control in a critically ill patient who needed medical optimization before surgery.
  • ||||||||||  rivaroxaban / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. (Pubmed Central) -  Aug 14, 2022   
    In patients with CVD, LD DOAC vs placebo on a background of antiplatelet therapy, reduced ischaemic events at the expense of increased major and all bleeding, but without significantly increasing intracranial or fatal bleeds, while the reduction of cardiovascular or total mortality and stroke was not statistically significant. A DPI with very LD DOAC (i.e. rivaroxaban 2.5 mg twice daily) appeared particularly advantageous, especially when combined with a single antiplatelet agent and used among patients at high ischaemic and low bleeding risk.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Journal, Adverse events:  Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. (Pubmed Central) -  Aug 14, 2022   
    The fatal AEs mainly manifested as serious bleeding, and most of them occurred in patients with concurrent multiple risk factors. Monitoring coagulation during rivaroxaban treatment is recommended in very high-risk ASCVD populations, and attention should be paid to prevention of medication errors.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. (Pubmed Central) -  Aug 13, 2022   
    The results highlight the potentially increased thrombotic risk associated with combination use. Ongoing post-marketing data collection of real patient case scenarios are essential to the establishment of consensus guidelines on how to prioritize initial reversal efforts and manage these patients during the course of their bleed.